Get the Stockscreener App
37.45
2.52%
-0.985
After Hours:
37.44
-0.005
-0.01%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $37.45, with a volume of 25.38M.
It is down -2.52% in the last 24 hours and down -23.91% over the past month.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$38.43
Open:
$37.44
24h Volume:
25.38M
Relative Volume:
1.11
Market Cap:
$166.72B
Revenue:
$46.77B
Net Income/Loss:
$15.45B
P/E Ratio:
10.80
EPS:
3.468
Net Cash Flow:
$4.40B
1W Performance:
-3.53%
1M Performance:
-23.91%
6M Performance:
-39.43%
1Y Performance:
-53.74%
1-Day Range:
$37.00
$37.69
1-Week Range:
$37.00
$39.27
52-Week Range:
$35.85
$81.44
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
37.52 | 171.43B | 46.77B | 15.45B | 4.40B | 3.468 |
|
LLY
Lilly Eli Co
|
917.72 | 883.28B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
237.27 | 586.06B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
208.33 | 391.56B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
188.47 | 297.77B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
149.81 | 295.52B | 54.72B | 14.02B | 15.32B | 7.1855 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Downgrade | TD Cowen | Buy → Hold |
| Mar-03-26 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-02-26 | Downgrade | Goldman | Buy → Neutral |
| Feb-24-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-24-26 | Downgrade | Kepler | Buy → Hold |
| Feb-23-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-12-26 | Upgrade | Jefferies | Underperform → Hold |
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Dec-08-25 | Downgrade | Argus | Buy → Hold |
| Oct-27-25 | Resumed | Jefferies | Underperform |
| Oct-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-29-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Sep-16-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Sep-09-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-13-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Aug-05-25 | Downgrade | UBS | Buy → Neutral |
| Jul-31-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-30-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-17-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Mar-13-25 | Upgrade | Kepler | Hold → Buy |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
The Best Healthcare Stocks to Buy With $50 Right Now - The Motley Fool
Novo Nordisk A/S stock faces headwinds from CagriSema trial setback amid buyback progress and compet - AD HOC NEWS
Novo Nordisk A/S stock rebounds on UBT251 trial data amid CEO turmoil and buyback momentum - AD HOC NEWS
Novo Nordisk A/S - GlobeNewswire Inc.
Novo Nordisk A/S Stock (ISIN: DK0062498333) Faces Headwinds from FDA Warning Amid GLP-1 Demand - AD HOC NEWS
Novo Nordisk A/S Stock Faces Brutal Choice: Can Oral Wegovy Rescue the Semaglutide Empire? - AD HOC NEWS
FDA Warning Tests Novo Nordisk Compliance And Reshapes NYSE NVO Risk Profile - Sahm
Novo Nordisk Telehealth Deal Weighs On Weak Share Price And Valuation - Sahm
NVO Stock Quote Price and Forecast - CNN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/SNVO - ChartMill
Novo Nordisk A/S (NVO) Expands Manufacturing to Support Rising Global Demand for GLP-1 Drugs - Finviz
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal - Finviz
Novo Nordisk 2026 Dividend Guide for UAE Investors - Bitget
Morgan Stanley Upgrades Novo Nordisk A/S (NVO) to Equal Weight From UnderweightHere's Why - Finviz
Novo Nordisk Faces Securities Probe And GLP-1 Compounding Crackdown - Sahm
Novo Nordisk (NVO) Reports 10% Sales Growth as Obesity Care Hits DKK 82B - Finviz
Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly - Sahm
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
NVO Earnings History & Surprises | EPS & Revenue Results | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill
Novo Nordisk’s New Sogroya Uses And Vivtex Deal Test Valuation Gap - Sahm
JPMorgan prices Digital Barrier Notes linked to Novo Nordisk (AMJB) with 24.25% digital return - Stock Titan
Static price chart | MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/100/0.1/18.12.26 | DE000MJ595A5 - marketscreener.com
Novo Nordisk A/S (NVO) Announces FDA Approval of Three New Indications for Sogroya - Finviz
Novo Nordisk A/S (NVO) and Vivtex Corporation Announce a Partnership - Finviz
Novo Nordisk Sales Warning Tests GLP-1 Reliance And Future Growth Story - Sahm
NVO Price History for Novo Nordisk A/S ADR Stock - Barchart.com
Novo Nordisk's Shares Drop 16.43% on CagriSema Setback and Legal Scrutiny Trading Volume Slides to 184th - Bitget
Jim Cramer Recommends Eli Lilly over Novo Nordisk - Finviz
Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment - Finviz
European ADRs Rose In US Trading, Led By HSBC And Sequans - Finimize
Ozempic Price War - Benzinga
Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027 - Sahm
Why did NVO stock crash over 14% today? Novo Nordisk’s weight-loss drug CagriSema misses trial goal agains - The Economic Times
European ADRs Slipped To Start The Week, With Pharma Leading Moves - Finimize
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):